Apogee Therapeutics (NASDAQ:APGE) Issues Quarterly Earnings Results

Apogee Therapeutics (NASDAQ:APGE) posted its quarterly earnings data on Monday. The company reported ($0.60) earnings per share for the quarter, meeting the consensus estimate of ($0.60), Yahoo Finance reports.

Apogee Therapeutics Stock Performance

Shares of APGE opened at $44.88 on Wednesday. Apogee Therapeutics has a twelve month low of $14.19 and a twelve month high of $72.29. The firm’s 50 day moving average price is $43.02 and its two-hundred day moving average price is $47.60. The firm has a market cap of $2.62 billion and a P/E ratio of -8.46.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Wedbush restated an “outperform” rating and issued a $87.00 price objective on shares of Apogee Therapeutics in a research report on Monday, May 13th. Bank of America began coverage on shares of Apogee Therapeutics in a research report on Friday, May 10th. They issued a “buy” rating and a $80.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $73.00.

Insider Buying and Selling at Apogee Therapeutics

In other Apogee Therapeutics news, insider Carl Dambkowski sold 5,995 shares of Apogee Therapeutics stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $37.60, for a total value of $225,412.00. Following the transaction, the insider now owns 294,793 shares of the company’s stock, valued at $11,084,216.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, insider Carl Dambkowski sold 5,995 shares of the business’s stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $37.60, for a total value of $225,412.00. Following the sale, the insider now owns 294,793 shares of the company’s stock, valued at $11,084,216.80. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Michael Thomas Henderson sold 40,000 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $40.62, for a total transaction of $1,624,800.00. Following the transaction, the chief executive officer now owns 1,434,487 shares of the company’s stock, valued at approximately $58,268,861.94. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 68,330 shares of company stock valued at $2,707,426. 36.10% of the stock is currently owned by corporate insiders.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.